Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.47 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 4/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.46 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715188 | 1.00 | SLC7A5 (0.56) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL836565 | 1.00 | SLC7A5 (0.56) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL6941161 | 0.98 | SLC7A5 (0.54) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL7422736 | 0.98 | SLC7A5 (0.54) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL7422737 | 0.98 | SLC7A5 (0.54) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL23056597 | 0.86 | SLC7A5 (0.47) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL8768451 | 0.82 | SLC7A5 (0.52) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL23422900 | 0.81 | SLC7A5 (0.42) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL2517387 | 0.81 | SLC7A5 (0.56) | SLC7A5AAK1LARS1ANPEPRNPEP | |
| SCHEMBL18756073 | 0.81 | SLC7A5 (0.34) | SLC7A5AAK1LARS1ANPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-3642200-B1 | PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3364958-B1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-1999037604-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZYMOGENETICS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0918747-A1 | INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF | SMITHKLINE BEECHAM PLC (GB) | 1999-06-02 | — | — | EP | disclosed |
| EP-0859784-A1 | THIO-SUBSTITUTED PEPTIDES AS INHIBITORS FOR METALLOPROTEINASES AND TNF LIBERATION | Darwin Discovery Limited (GB) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1997043249-A1 | INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF | SMITHKLINE BEECHAM PLC (GB) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997012902-A1 | THIO-SUBSTITUTED PEPTIDES AS INHIBITORS FOR METALLOPROTEINASES AND TNF LIBERATION | DARWIN DISCOVERY LIMITED (GB) | 1997-04-10 | — | — | WO | disclosed |
| EP-0689538-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021625-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-09-29 | — | — | WO | disclosed |
| EP-0376012-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | SLC7A5 374/4885AAK1 1942/4885LARS1 3423/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885AAK1 2350/4885LARS1 2380/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885AAK1 2350/4885LARS1 2380/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885AAK1 2350/4885LARS1 2380/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885AAK1 2350/4885LARS1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.